U.S. Contraceptive Market Set to Witness an Uptick during 2020 to 2027

Posted by Mrudula Anil Karmarkar on January 27th, 2022

The U.S. contraceptive market size is expected to reach USD 10 billion by 2027 registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. Improving access and awareness regarding Long-Acting Reversible Contraceptives (LARCs) and the effectiveness and convenience of using these products are expected to drive the growth of the market. The Guttmacher Institute reports 60% of women of reproductive age use contraception in the U.S. Use of hormonal contraceptives other than the birth control pill has significantly increased in married women.

Key market players are actively investing in the clinical pipeline, resulting in high competition and an increase in the quality of contraceptives. In January 2020, Mithra Pharmaceuticals announced the success of Estelle’s phase 3 study conducted in the U.S. and Canada, meeting the primary efficacy endpoint. The efficacy was reported to be similar to a recently FDA-approved Annovera & Lo-Loestrin. In August 2020, Agile Therapeutics, Inc. reported that the company is on track to request FDA approval for Twirla. The company is expected to conduct a review with the U.S. FDA’s advisory committee in October 2020 for Twirla’s New Drug Application.

Increasing awareness regarding the importance of sexual and reproductive health in women in the age group of 15-49 years is expected to boost the use of various birth control methods. Modern contraceptive methods, such as condoms, pills, and implants, are preferred by women of the age group 15 to 29 years. In 2018, 43 million women in the U.S. were at the risk of unintended pregnancy. According to the CDC, 19.5 million women still lack access to healthcare centers offering a full range of contraceptive methods.

Women living in smaller counties have limited access to modern birth control, which leads to unwanted pregnancy or abortion. Thus, increasing demand for contraceptives is likely to aid market growth. According to the Patient Protection and Affordable Care Act, all contraceptive methods authorized by the FDA must be covered by private insurance. The federal and state governments also provide reimbursements for family planning services and supplies to help women.

Download Free Sample Report @

https://www.grandviewresearch.com/industry-analysis/us-contraceptive-market/request/rs1

The Covid-19 pandemic has significantly impacted the U.S. healthcare sector. The contraceptives market is majorly dependent on physician-prescribed and physician-administered products. Due to restrictions on visiting physician offices without an emergency, the demand for contraceptive products was low during the first few months of the pandemic. Telehealth services and virtual consultations were recommended for contraceptive screening and counseling.

U.S. Contraceptive Market Report Highlights

• The prevalence of teenage pregnancies is highest in the U.S. Government initiatives, such as improving sex education and increasing access to contraceptives, is expected to boost the adoption of various birth control methods in the country
• In 2020, the pills segment held the largest market share owing to the convenience of use and easy availability. The contraceptive pills market in the country is highly competitive due to the presence of generic products
• Intrauterine Devices (IUDs) was also among the major product segments in 2020 and will expand further at a steady CAGR from 2020 to 2027 with increasing demand for hormonal IUDs
• The rapid growth of subdermal implants in the U.S. contraceptive market is anticipated in the coming years. The subdermal implants market is highly consolidated with the presence of very few players
• Key companies in this market are focusing more on M&A and product development to gain a competitive edge over others
• In February 2020, TherapeuticsMD, Inc. entered into an agreement with Afaxys Pharma, LLC to increase access to ANNOVERA in the U.S. public health sector
• In February 2020, Agile Therapeutics, Inc. received FDA approval for the sale of Twirla in the U.S.

The regional market is highly competitive due to the presence of several companies. Most of the companies are undertaking strategic initiatives, such as investments in R&D for developing innovative products and to gain a competitive edge over others. In February 2020, Afaxys, Inc. and TherapeuticsMD, Inc. signed an agreement to increase access to Annovera in the U.S. public healthcare system. In July 2020, TherapeuticsMD, Inc. entered into an agreement with Nurx—an online company for women’s health—for increasing its access to Annovera. High investments by prominent companies for the commercialization of effective and long-term reversible contraceptives have increased the awareness levels about these products. Some of the prominent companies in the U.S. contraceptive market include:

• Church & Dwight Co., Inc.
• Reckitt Benckiser Group Plc
• Veru, Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• The Cooper Companies, Inc.
• Mayer Laboratories, Inc.
• Agile Therapeutics

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.